ClinicalTrials.gg
CompletedNCT02203032NAVIGATEUpdated Sep 12, 2017Results posted

A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab

A Phase 3 interventional study of Ustekinumab and Guselkumab in Psoriasis, sponsored by Janssen Research & Development, LLC. Completed at 87 sites in 10 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2017-09-12.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
872
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing ustekinumab in Psoriasis — 4 open to participants now, 4 under way, none of them phase 3. Ustekinumab · Psoriasis.

Enrollment
3rd of 31
872 · median 158
Started
2014
with 3 others
Phase 3
16 of 31
none open now
Registered
20th of 31
by date
Lead sponsor
6 of 31
Janssen Research & Development, LLC

Among the 31 studies testing ustekinumab in Psoriasis, this one is the 3rd largest by enrollment, is one of 4 that started in 2014, is one of 16 in phase 3, and was the 20th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

4 of the 31 studies testing ustekinumab in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About ustekinumab

Ustekinumab: first FDA approval 2009 (STELARA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing ustekinumab in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis (scaly skin rash) who had inadequate response to ustekinumab.

Read the detailed description

This is a randomized (assignment of study drug by chance), double-blind (participants nor study staff will know the identity of study drugs), multicenter study to evaluate efficacy and safety of guselkumab for the treatment of participants with moderate to severe plaque-type psoriasis who had an inadequate response to ustekinumab. The study will consist of a screening period, open-label and double-blind treatment periods, and a follow-up period. The treatment period will have 2 phases: an open-label treatment phase during which all participants will receive ustekinumab at Weeks 0 and 4 and a blinded treatment phase during which participants with an inadequate Investigator's Global Assessment response (IGA≥2) to ustekinumab at Week 16 will be randomized to receive either guselkumab or ustekinumab through Week 44. Participants with an IGA response of 0 or 1 (cleared or minimal disease) at Week 16 will continue to receive open-label treatment with ustekinumab every 12 weeks through Week 40. All participants will complete a follow-up phase through Week 52 for efficacy and through Week 60 for safety evaluations. The total duration of the study will be approximately 64 weeks (includes a 4-week screening period). Participants' safety will be monitored throughout the study.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Psoriasis
  • Plaque-type psoriasis
  • Guselkumab
  • Ustekinumab
  • CNTO 1959
  • Monoclonal antibody
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of plaque-type psoriasis (with or without psoriatic arthritis for at least 6 months before the first administration of study drug
  • Have a Psoriasis Area and Severity Index (PASI) greater than or equal to (>=) 12 at Screening and at Baseline
  • Have an Investigator's Global Assessment (IGA) >=3 at Screening and at Baseline
  • Have an involved body surface area (BSA) >= 10 percent (%) at Screening and at Baseline
  • Be a candidate for phototherapy or systemic treatment for psoriasis (either naïve or history of previous treatment)

Exclusion criteria

Exclusion Criteria:

  • Has a history or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
  • Has unstable cardiovascular disease, defined as a recent clinical deterioration (example [eg], unstable angina, rapid atrial fibrillation) in the last 3 months or a cardiac hospitalization within the last 3 months
  • Currently has a or has a history of malignancy within 5 years before Screening (with the exception of a nonmelanoma skin cancer that has been adequately treated with no evidence of recurrence for at least 3 months before the first study drug administration, or cervical carcinoma in situ that has been treated with no evidence of recurrence for at least 3 months before the first study drug administration)
  • Has previously received guselkumab or ustekinumab
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
872 participants (actual)

Study arms

  • Experimental
    Open-label ustekinumab

    Drug: Ustekinumab

  • Experimental
    Double-blind guselkumab

    Drug: Guselkumab · Drug: Placebo for ustekinumab

  • Experimental
    Double-blind ustekinumab

    Drug: Ustekinumab · Drug: Placebo for guselkumab

Interventions

  • 45 mg or 90 mg given by subcutaneous injection at Weeks 0 and 4 for all participants. Participants with an IGA score of 0 or 1 at Week 16 will also receive ustekinumab every 12 weeks (q12w) from Week 16 to Week 40.

  • 100 mg given by subcutaneous injection at Weeks 16 and 20 and every 8 weeks (q8w) thereafter through Week 44.

  • DrugPlacebo for ustekinumab

    Subcutaneous injection at Weeks 16, 28, and 40 to maintain the blind for participants randomized to treatment with guselkumab.

  • DrugPlacebo for guselkumab

    Subcutaneous injection at Weeks 16 and 20 and q8w thereafter through Week 44 to maintain the blind for participants randomized to treatment with ustekinumab.

06

What researchers measure

Primary outcomes

  1. Number of Visits at Which Participants Achieved an Investigator's Global Assessment (IGA) Response of Cleared (0) or Minimal (1) and at Least a 2 Grade Improvement (From Week 16) From Week 28 Through Week 40

    The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participants' psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

    Time frame: Week 28 through Week 40

Secondary outcomes

  1. Number of Visits at Which Participants Achieved a Psoriasis Area and Severity Index (PASI) 90 Response From Week 28 Through Week 40

    The PASI is a system used for assessing and grading the severity of psoriatic lesions. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 to 6, and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants who achieved at least a 90 percent improvement from baseline in the PASI score.

    Time frame: Week 28 through Week 40

  2. Number of Visits at Which Participants Achieved an IGA Score of Cleared (0) From Week 28 Through Week 40

    The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participants' psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

    Time frame: Week 28 through Week 40

  3. Percentage of Participants With an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) and at Least a 2 Grade Improvement (From Week 16) at Week 28

    The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participants' psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

    Time frame: Week 28

07

Results

Posted Jul 17, 2017

Participant flow

Open Label Run-in (Week 0 to Week 16)
Participant flow — Open Label Run-in (Week 0 to Week 16)
MilestoneUstekinumab (Open Label Run-in)100 mg Guselkumab (Randomized)Ustekinumab (Randomized)Ustekinumab (Nonrandomized Open Label Continuation)
Started872000
Treated871000
Completed853000
Not completed19000
Withdrew: Adverse event2000
Withdrew: Lack of efficacy1000
Withdrew: Lost to follow-up3000
Withdrew: Withdrawal by subject6000
Withdrew: Protocol violation4000
Withdrew: Other2000
Withdrew: Enrolled but not treated1000
Blinded Phase (Week 16 to Week 44)
Participant flow — Blinded Phase (Week 16 to Week 44)
MilestoneUstekinumab (Open Label Run-in)100 mg Guselkumab (Randomized)Ustekinumab (Randomized)Ustekinumab (Nonrandomized Open Label Continuation)
Started0135133585
Completed0120107539
Not completed0152646
Withdrew: Lost to follow-up0238
Withdrew: Withdrawal by subject081920
Withdrew: Other04115
Withdrew: Death0001
Withdrew: Completed safety follow-up0132

Outcome measures

PrimaryNumber of Visits at Which Participants Achieved an Investigator's Global Assessment (IGA) Response of Cleared (0) or Minimal (1) and at Least a 2 Grade Improvement (From Week 16) From Week 28 Through Week 40

The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participants' psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Time frame:
Week 28 through Week 40
Reported as:
Mean · visits
Number of Visits at Which Participants Achieved an Investigator's Global Assessment (IGA) Response of Cleared (0) or Minimal (1) and at Least a 2 Grade Improvement (From Week 16) From Week 28 Through Week 40
visitsGuselkumab (Randomized)Ustekinumab (Randomized)
Number of Visits at Which Participants Achieved an Investigator's Global Assessment (IGA) Response of Cleared (0) or Minimal (1) and at Least a 2 Grade Improvement (From Week 16) From Week 28 Through Week 401.5 ± 1.570.7 ± 1.26
Statistical analysis
  • Guselkumab (Randomized) vs Ustekinumab (Randomized) · Row mean score test · p = < 0.001
SecondaryNumber of Visits at Which Participants Achieved a Psoriasis Area and Severity Index (PASI) 90 Response From Week 28 Through Week 40

The PASI is a system used for assessing and grading the severity of psoriatic lesions. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 to 6, and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants who achieved at least a 90 percent improvement from baseline in the PASI score.

Time frame:
Week 28 through Week 40
Reported as:
Mean · visits
Number of Visits at Which Participants Achieved a Psoriasis Area and Severity Index (PASI) 90 Response From Week 28 Through Week 40
visitsGuselkumab (Randomized)Ustekinumab (Randomized)
Number of Visits at Which Participants Achieved a Psoriasis Area and Severity Index (PASI) 90 Response From Week 28 Through Week 402.2 ± 1.691.1 ± 1.53
Statistical analysis
  • Guselkumab (Randomized) vs Ustekinumab (Randomized) · Row mean score test · p = < 0.001
SecondaryNumber of Visits at Which Participants Achieved an IGA Score of Cleared (0) From Week 28 Through Week 40

The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participants' psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Time frame:
Week 28 through Week 40
Reported as:
Mean · visits
Number of Visits at Which Participants Achieved an IGA Score of Cleared (0) From Week 28 Through Week 40
visitsGuselkumab (Randomized)Ustekinumab (Randomized)
Number of Visits at Which Participants Achieved an IGA Score of Cleared (0) From Week 28 Through Week 400.9 ± 1.340.4 ± 1.06
Statistical analysis
  • Guselkumab (Randomized) vs Ustekinumab (Randomized) · Row mean score test · p = < 0.001
SecondaryPercentage of Participants With an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) and at Least a 2 Grade Improvement (From Week 16) at Week 28

The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participants' psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Time frame:
Week 28
Reported as:
Number · percentage of participants
Percentage of Participants With an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) and at Least a 2 Grade Improvement (From Week 16) at Week 28
percentage of participantsGuselkumab (Randomized)Ustekinumab (Randomized)
Percentage of Participants With an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) and at Least a 2 Grade Improvement (From Week 16) at Week 2831.114.3
Statistical analysis
  • Guselkumab (Randomized) vs Ustekinumab (Randomized) · Cochran-Mantel-Haenszel · p = = 0.001

Adverse events

Collected over Up to Week 60. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ustekinumab (Open Label Run-in)—11/871 (1.3%)80/871 (9.2%)
100 mg Guselkumab (Randomized)—9/135 (6.7%)37/135 (27.4%)
Ustekinumab (Randomized)—6/133 (4.5%)33/133 (24.8%)
Ustekinumab (Nonrandomized Open Label Continuation)—20/585 (3.4%)60/585 (10.3%)
Most frequent serious events
Showing 10 of 45
Most frequent serious events
EventUstekinumab (Open Label Run-in)100 mg Guselkumab (Randomized)Ustekinumab (Randomized)Ustekinumab (Nonrandomized Open Label Continuation)
Myocardial InfarctionCardiac disorders0/8712/1350/1330/585
Acute Myocardial InfarctionCardiac disorders0/8710/1351/1331/585
Back PainMusculoskeletal and connective tissue disorders0/8710/1351/1330/585
EczemaSkin and subcutaneous tissue disorders0/8710/1351/1330/585
Diabetes MellitusMetabolism and nutrition disorders0/8710/1351/1330/585
Type 2 Diabetes MellitusMetabolism and nutrition disorders0/8710/1351/1330/585
Retinal DetachmentEye disorders0/8710/1351/1330/585
Angina UnstableCardiac disorders0/8711/1350/1330/585
Toxicity to Various AgentsInjury, poisoning and procedural complications0/8711/1350/1330/585
Transitional Cell CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/8711/1350/1330/585
Most frequent other events
Most frequent other events
EventUstekinumab (Open Label Run-in)100 mg Guselkumab (Randomized)Ustekinumab (Randomized)Ustekinumab (Nonrandomized Open Label Continuation)
NasopharyngitisInfections and infestations47/87123/13523/13333/585
Upper Respiratory Tract InfectionInfections and infestations33/87115/13511/13327/585

Baseline characteristics

Baseline analysis included all participants who were enrolled at Week 0 and received at least 1 dose of study agent administration.

Age, Categorical
Age, Categorical(Participants)Ustekinumab (Open Label Run-in)
<=18 years4
Between 18 and 65 years814
>=65 years53
Age, Continuous
Age, Continuous(years)Ustekinumab (Open Label Run-in)
Mean43.1 ± 13.21
Sex: Female, Male
Sex: Female, Male(Participants)Ustekinumab (Open Label Run-in)
Female305
Male566
Region of Enrollment
Region of Enrollment(participants)Ustekinumab (Open Label Run-in)
Germany96
Poland294
Russia88
Spain24
United Kingdom11
Canada61
United States194
Australia19
Korea, Republic Of29
Taiwan, Province Of China55
08

Study locations

87 sites
  • Birmingham, Alabama, United States
  • Bakersfield, California, United States
  • Los Angeles, California, United States
  • Santa Monica, California, United States
  • Coral Gables, Florida, United States
  • Ocala, Florida, United States
  • Alpharetta, Georgia, United States
  • Atlanta, Georgia, United States
  • Arlington Heights, Illinois, United States
  • Chicago, Illinois, United States
  • Skokie, Illinois, United States
  • Indianapolis, Indiana, United States
  • Plainfield, Indiana, United States
  • Louisville, Kentucky, United States
  • Boston, Massachusetts, United States
  • Troy, Michigan, United States
  • Buffalo, New York, United States
  • New York, New York, United States
  • Portland, Oregon, United States
  • Pittsburgh, Pennsylvania, United States
  • Johnston, Rhode Island, United States
  • Nashville, Tennessee, United States
  • Arlington, Texas, United States
  • Austin, Texas, United States
  • Dallas, Texas, United States
  • San Antonio, Texas, United States
  • Webster, Texas, United States
  • Norfolk, Virginia, United States
  • Spokane, Washington, United States
  • Fremantle, Australia
  • Victoria Park, Australia
  • Woden, Australia
  • Woolloongabba, Australia
  • Surrey, British Columbia, Canada
  • Vancouver, British Columbia, Canada
  • Moncton, New Brunswick, Canada
  • Halifax, Nova Scotia, Canada
  • Ajax, Ontario, Canada
  • Richmond Hill, Ontario, Canada
  • Montreal, Quebec, Canada
  • Quebec, Canada
  • Berlin, Germany
  • Bonn, Germany
  • Essen, Germany
  • Gera, Germany
  • Hamburg, Germany
  • Leipzig, Germany
  • Lübeck, Germany
  • Mahlow, Germany
  • Munster, Germany
  • Witten, Germany
  • Anyang, Korea, Republic of
  • Incheon, Korea, Republic of
  • Seoul, Korea, Republic of
  • Bialystok, Poland
  • Bydgoszcz, Poland
  • Gdansk, Poland
  • Krakow, Poland
  • Lodz, Poland
  • Lublin, Poland
  • Olsztyn, Poland
  • Poznan, Poland
  • Poznań, Poland
  • Torun, Poland
  • Warszawa, Poland
  • Wroclaw, Poland
  • Łódź, Poland
  • Chelyabinsk, Russian Federation
  • Ekaterinburg, Russian Federation
  • Krasnodar, Russian Federation
  • Lipetsk, Russian Federation
  • St-Petersburg, Russian Federation
  • Stavropol, Russian Federation
  • Ufa, Russian Federation
  • Alcorcon, Spain
  • Alicante, Spain
  • Barcelona, Spain
  • La Coruña, Spain
  • Madrid, Spain
  • Taichung, Taiwan
  • Tainan, Taiwan
  • Taipei, Taiwan
  • Taoyuan, Taiwan
  • Dudley, United Kingdom
  • Dundee, United Kingdom
  • London, United Kingdom
  • Salford, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2014 to primary completion in Dec 2015, 14 months.

Results were first posted in Jul 2017, 1 year 6 months after primary completion. A results delay was requested in Jul 2016.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 14 months is close to that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2014
First posted
Jul 29, 2014
StartActual
Oct 7, 2014
Primary completionActual
Dec 25, 2015
CompletionActual
May 24, 2016
Results delay requested
Jul 12, 2016
Results first posted
Jul 17, 2017
Last update
Sep 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02203032
Responsible party
Sponsor
First posted
Jul 29, 2014
Start date
Oct 7, 2014
Primary completion
Dec 25, 2015
Completion
May 24, 2016
Results posted
Jul 17, 2017
Last update
Sep 12, 2017

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ustekinumab · Guselkumab

Start the discussion